Visit us at the AAO-HNSF 2022 Annual Meeting – Booth 2221

Diagnostic Uncertainty

In Indeterminate Thyroid Nodules

View Validation Study

Multiplatform molecular test performance in indeterminate thyroid nodules

Watch Webinar

Overcoming Diagnostic Uncertainty Using the Markers That Matter™

Accurate risk stratification can help reduce unnecessary thyroid surgery and assist pre-operative patient counseling and surgical planning.2

Markers That MatterTM

Strategically designed rule-in / rule-out testing platform—maximizing your understanding of true negatives, true positives, and aggressive biological features of thyroid cancer

Performance Matters

Demonstrated High PPV and NPV*1

50 %
Low Risk Category
50 %
High Risk Category
50 %
Low Risk Category
40 %
High Risk Category

*Performance prevalence-adjusted to histopathologic subtypes. 3-category performance aligned to clinical decision-making in Bethesda III and IV nodules.1,2

Study Design

Multicenter, retrospective, blinded validation study of 309 subjects with indeterminate thyroid nodules (Bethesda III, IV, or V) and corresponding surgical histology. Gold-standard unanimous consensus histopathology diagnosis (n=197) among three pathologists was used, and all molecular testing was performed using archived cytology smears. Results were reported in 3 categories (negative, moderate, or positive) based on the combined test results from both ThyGeNEXT® (mutation panel) and ThyraMIR® (microRNA risk classifier). The proportion of benign and malignant histopathologic subtypes within this study vastly differed from those found within a recent prospective study.1,3 Histopathologic subtype prevalence adjustments were used to determine the impact of these differences on test performance.4 The analysis showed that test performance was optimal after prevalence adjustments.

The 3-category microRNA and mutation panel combination test had a high PPV (positive predictive value) at 75% and high NPV (negative predictive value) at 97% (n=178) after prevalence adjustments.1 Prevalence-unadjusted, PPV and NPV were 74% and 95%, respectively, for the 3-category approach.1

microRNA classification further risk-stratified patients with weak driver mutations, including RAS, resulting in four out of five nodules being accurately ruled-in or ruled-out for disease.1

Flexibility Matters

Interpace Diagnostics is the only company that offers:

Testing of fresh FNA samples or direct smears/ThinPrep® slides

No special shipping or refrigeration requirements

Mutation panel + miRNA expression classifier

Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.


1. Lupo MA, et al. Diagn Cytopathol. 2020;1–11. 2. Banizs AB, Silverman JF. Diagn Cytopathol. 2019;47(4):268-274. 3. Steward DL, et al. JAMA Oncol. 2019;5(2):204-212. 4. Usher-Smith JA, et al. BMJ. 2016;353:i3139.

Scroll to Top